Evidence map›Paper›PMID 34532768›Full record

Trial reportEuropean radiology experimental2021

3-T MRI and clinical validation of ultrasound-guided transperineal laser ablation of benign prostatic hyperplasia.

Guglielmo Manenti, Tommaso Perretta, Antonello Calcagni, Donatella Ferrari, Colleen P Ryan, Federico Fraioli, Rosaria Meucci, Andrea Malizia, Valerio Iacovelli, Enrico Finazzi Agrò and 1 more

3 registry-linked trialsOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European radiology experimental, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04044573 naunknown statusnot on this map

Efficacy of Ultrasound Guided Percutaneous Transperineal Laser Ablation in Benign Prostatic Hypertrophy Patients: Non-Pharmacological Interventional Study

TypeinterventionalSponsorUniversity of Rome Tor VergataRan2018 to 2023Enrolled40ConditionsBenign Prostatic Hyperplasia, Lower Urinary Tract SymptomsArmsTransperineal Focal Laser Ablation (TPLA)
NCT06564415 recruitingnot on this mapstarted 2024, after this paper: background citation

European Registry for Transperineal Laser Ablation of Prostate (TPLA) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Obstruction (BPO)

Typeobservational_patient_registrySponsorUniversity of FlorenceRan2024 to 2034Enrolled2,500ConditionsBenign Prostatic Hyperplasia, Prostatic DiseasesArmsTransperineal Laser Ablation of Prostate
NCT07016620 recruitingnot on this mapstarted 2026, after this paper: background citation

In-Office Transperineal Laser Ablation (TPLA) as a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia (BPH) After Minimally Invasive Surgical Therapies (MIST)

TypeobservationalSponsorThe Cleveland ClinicRan2026 to 2027Enrolled20ConditionsBenign Prostatic Hyperplasia (BPH)ArmsTransperineal Laser Ablation (TPLA)
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Guglielmo ManentiDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133, Rome, Italy. gu.manenti@gmail.com.ORCID 0000-0002-7659-5392
Tommaso PerrettaDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133, Rome, Italy.
Antonello CalcagniDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133, Rome, Italy.
Donatella FerrariDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133, Rome, Italy.
Colleen P RyanDepartment of Neuromotor Physiology, Fondazione Santa Lucia IRCCS, Rome, Italy.
Federico FraioliDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133, Rome, Italy.
Rosaria MeucciDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133, Rome, Italy.
Andrea MaliziaDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133, Rome, Italy.
Valerio IacovelliDepartment of Urology, University of Rome "Tor Vergata", 00133, Rome, Italy.
Enrico Finazzi AgròDepartment of Urology, University of Rome "Tor Vergata", 00133, Rome, Italy.
Roberto FlorisDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133, Rome, Italy.
University of Rome Tor Vergata · ITFondazione Santa Lucia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTransperineal laser ablation (TPLA) of the prostate is a novel, mini-invasive option for men with lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH). Our aim was to assess the impact of ultrasound-guided TPLA regarding urodynamic improvement and sexual function, monitoring clinical data, postprocedural complications and imaging findings at 3-T multiparametric magnetic resonance imaging.

methodsForty-four patients aged ≥ 50 affected with moderate to severe LUTS (International Prostate Symptoms score ≥ 12) due to benign prostatic obstruction and refractoriness, intolerance or poor compliance to medical therapies underwent US-guided TPLA between May 2018 and February 2020. Clinical measurements included PSA, uroflowmetry, sexual function assessment (using the International Index of Erectile Function and Male Sexual Health Questionnaire-Ejaculatory Dysfunction short form) and quality of life questionnaire. Adverse events were evaluated using the Clavien-Dindo scale. Volume changes were measured by MRI and automatic segmentation software during 1-year follow-up. Registration: NCT04044573 - May 5th, 2018, https://www.clinicaltrials.gov

resultsMRI assessed the changes over time with a 53% mean reduction of adenoma volume and 71% of the ablated area, associated with clinical and functional improvement and resolution of LUTS in all cases. Five of 44 patients (11.3%) had urinary blockage due to clots and required re-catheterisation for 2 weeks. The overall adverse event rate was 7%.

conclusionUS-guided TPLA performed as a safe, manageable and effective treatment for LUTS. It could be considered an alternative effective mini-invasive procedure to standard treatments for BPH in the outpatient setting.

Indexed as

Laser TherapyProstatic HyperplasiaHumansMagnetic Resonance ImagingMaleMiddle AgedQuality of LifeUltrasonography, InterventionalLaser therapyLower urinary tract symptomsMagnetic resonance imagingProstatic hyperplasia

Identifiers

PMID34532768
PMCPMC8445741
OpenAlexW3200754247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.